A Phase 3 interventional study of Lidocaine (Zingo) and Placebo in Catheter Site Pain, Pain, Acute and Anesthesia, Local, sponsored by Lee's Pharmaceutical Limited. Completed at 1 site in China. Open to participants aged 3 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-24.
Sponsored by Lee's Pharmaceutical Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing lidocaine in Acute Pain — 2 open to participants now, 3 under way, none of them phase 3. Lidocaine · Acute Pain.
Among the 20 studies testing lidocaine in Acute Pain, this one is the 3rd largest by enrollment, is one of 3 that started in 2018, is one of 2 in phase 3, and was the 10th registered.
1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.
Browse Acute Pain studies →2 of the 20 studies testing lidocaine in Acute Pain are open now, in 1 country. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
Community Medical Center, Toms River, NJ · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 3 Years to 12 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 7
First in 2015; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 288 is above the median of 86 across 903 interventional studies indexed under Acute Pain.
Median enrollment 66 across the 20 interventional studies. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 20 have an industry lead sponsor. The 10 most frequent:
Lee's Pharmaceutical Limited is the lead sponsor of 74 studies on the registry; 6 are open to participants now.
Lee's Pharmaceutical Limited has 1 study filed under Acute Pain — fewer than ten, so there is no comparison to draw.
1 of the studies testing lidocaine in Acute Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07068243Duke UniversityREctus Sheath Trial | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing lidocaine in Acute Pain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy and safety of Zingo in treating pain associated with venipunture and peripheral venous cannulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.5mg lidocaine at 20 bar pressure
Drug: Lidocaine (Zingo)
no emitted particle at 20 bar pressure, identical in external appearance to Zingo
Drug: Placebo
0.5 mg lidocaine, 20 bar pressure
Also known as: Zingo
Placebo injector, 20 Bar pressure, empty injector
Wong-Baker FACES Pain Rating Scale After Venipuncture or Peripheral Cannulation
Child's assessment of pain on venipuncture or peripheral venous cannulation (all ages) performed one to three minutes after Zingo/Placebo administration, measured using the Wong-Baker FACES pain rating scale. The scale includes pictures of facial expressions with correlating numerical scale of 0-10, 0 being no hurt and 10 being the worst hurt.
Time frame: immediate after venipunture
100-mm Visual Analogue Scale (VAS)
Assessment of pain on venipuncture or peripheral venous cannulation by children age 8-12, measured using a 100-mm VAS (0-100) anchored at 0 for "no pain" and at 100 for "worst possible pain."
Time frame: immediate after venipunture
Response Rate
Percentage of subject who score 0 or 1 in the FACES Pain Rating Scale
Time frame: immediate after venipunture
Compliance Score
Compliance to venipuncture assess by investigator
Time frame: immediate after venipunture
Adverse Event Frequency
Time frame: 1 day
Adverse Event Severity
Time frame: 1 day
Comfort of Zingo/Placebo Administration (Wong-Baker)
Subject (all ages) to assess the level of comfort of Zingo/Placebo administration, measured using the Wong-Baker FACES scale (0-10), where 0 represent No Discomfort and 10 represent Worst Possible Discomfort.
Time frame: immediate after venipunture
Comfort of Zingo/Placebo Administration (VAS)
Subject (age 8-12) to assess the level of comfort of Zingo/Placebo administration, measured using VAS pain rating scales (0-100), where 0 represent No Discomfort and 100 represent Worst Possible Discomfort.
Time frame: immediate after venipunture
Local Adverse Reaction
Local Adverse Reactions including erythema, edema, pruritus and hemorrhage/petechiae by severity.
Time frame: Pre-dose (0-1 hour before), immediately after dose, 15 minutes, 30 minutes
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2018 to primary completion in Feb 2019, 6 months.
Of 29 industry-sponsored phase 3 interventional studies under Acute Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 6 months is below that.
Counting every sponsor, half of 54 studies reached it within 14 months; a quarter within 7 and three quarters within 25.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidocaine
Lee's Pharmaceutical Limited →